3 of the Best Stocks to Buy for Less Than $100 Right Now

The article highlights Netflix (~$74; ~24x trailing earnings) as a discounted long-term growth stock after $45B revenue last year (+34% vs two years ago) and ~$11B earnings (about $0.24 of profit per $1 of revenue). For value/dividend investors, Pfizer (~$24; forward P/E ~8; ~7.1% dividend yield) is framed as safer with solid expectations and ~20 key pivotal studies underway, while Verizon (~$42; forward P/E ~8; ~6.7% yield) is positioned for improved growth after completing its acquisition of Frontier. Overall, it argues these three stocks offer upside from current depressed valuations, but the piece does not cite new earnings or guidance changes.

Analysis

The only name here with a clean rerating path is NFLX: the market is already paying for execution, but the business still has operating leverage if content spend stays disciplined and ad-tier monetization lifts ARPU. The risk is that the multiple is already reflecting a lot of that quality; if revenue growth slips even modestly or margin expansion stalls, the stock can de-rate quickly because there is no balance-sheet story to cushion it.

PFE and VZ screen cheap for a reason. Both are effectively being valued as cash-yield vehicles, so the main question is not absolute valuation but dividend durability versus capital intensity. For PFE, the catalyst window is binary and lumpy over the next 1-3 quarters: one or two positive study readouts can reset sentiment, but absent that, the stock likely remains a yield trap with limited multiple expansion. For VZ, the competitive issue is less market share and more free-cash-flow conversion; if integration costs or debt service crowd out incremental capital returns, the equity behaves like a bond proxy, not a growth compounder.

Contrarian view: the crowd may be overconfident that all three deserve a simple "cheap = buy" label. NFLX is not cheap on normalized earnings quality, while PFE/VZ may be under-owned for good fundamental reasons. The better trade is relative quality versus value trap, not a blanket long basket. What would falsify the bearish view on PFE/VZ is sustained guidance raise plus visible FCF coverage above dividend obligations; what would falsify the bullish NFLX view is any sign of slower subscriber monetization or margin compression over the next two earnings cycles.

Key Decisions for Investors

• Long NFLX / short PFE pair trade into the next 1-2 earnings cycles: own the name with the clearest operating leverage and short the one most dependent on discrete pipeline catalysts; target is multiple divergence, not absolute market direction.
• Avoid initiating fresh long PFE until at least one pivotal readout or management guidance revision confirms dividend coverage; otherwise treat as a 6-12 month income hold, not a re-rating catalyst.
• Hold VZ only as a defensive yield position if 10Y Treasury yields soften; if rates stay elevated and FCF does not improve post-Frontier, expect the stock to continue behaving like a capped-upside bond substitute.
• Buy NFLX on 5-8% pullbacks rather than chasing strength; risk/reward is best when short-term momentum resets but the monetization story remains intact.
• Set an alert on PFE around upcoming study data and on VZ around FCF/dividend coverage commentary; either can falsify the low-multiple thesis quickly.